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Abstract
Background
This paper is aimed to (i) develop an innovative classification of COPD, multi-dimensional
phenotype, based on a multidimensional assessment; (ii) describe the identified multi-
dimensional phenotypes.
Methods
An exploratory factor analysis to identify the main classificatory variables and, then, a cluster
analysis based on these variables were run to classify the COPD-diagnosed 514 patients
enrolled in the STORICO (trial registration number: NCT03105999) study into multi-dimen-
sional phenotypes.
Results
The circadian rhythm of symptoms and health-related quality of life, but neither comorbidity
nor respiratory function, qualified as primary classificatory variables. Five multidimensional
phenotypes were identified: the MILD COPD characterized by no night-time symptoms and
the best health status in terms of quality of life, quality of sleep, level of depression and anxi-
ety, the MILD EMPHYSEMATOUS with prevalent dyspnea in the early-morning and day-
time, the SEVERE BRONCHITIC with nocturnal and diurnal cough and phlegm, the
SEVERE EMPHYSEMATOUS with nocturnal and diurnal dyspnea and the SEVERE
MIXED COPD distinguished by higher frequency of symptoms during 24h and worst quality
of life, of sleep and highest levels of depression and anxiety.
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Conclusions
Our results showed that properly collected respiratory symptoms play a primary classifica-
tory role of COPD patients. The longitudinal observation will disclose the discriminative and
prognostic potential of the proposed multidimensional phenotype.
Trial registration
Trial registration number: NCT03105999, date of registration: 10th April 2017.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella definition encompassing a
variety of clinical and pathophysiological conditions. Selected clinical phenotypes, namely the
bronchitic, the emphysematous and the asthma-like, have been repeatedly recognized, but dis-
ease pattern not always univocally conforms to one of them [1]. Indeed, the clinical presenta-
tion frequently resembles a mixture of the classical phenotypes. Furthermore, comorbidity and
age itself largely shape the clinical and health status of COPD patients. Indeed, a senescence-
associated secretory phenotype has been identified and might affect the clinical expression of
COPD in the elderly [2]. Unfortunately, large pharmacological randomized clinical trials
(RCTs) could not shed light on phenotypic variability due to the stringent selecting criteria.
Further complicating this issue is the lack of attention to the circadian rhythm of respiratory
symptoms in RCTs. On the other hand, several observational studies point out at circadian
symptom variability as a correlate of disease severity [3] or a distinctive clinical trait [4] or a
correlate of derangement of selected health status dimensions [5]. Furthermore, nocturnal
symptoms are reported by the majority of COPD patients [6] and dramatically increased with
age in a COPD population over 65 [7]. However, circadian rhythm variability in COPD is only
marginally and partially explored in selected RCT with the only intent of providing 24 hours
pharmacological coverage and, then, symptoms control. Thus, how circadian rhythm of symp-
toms affects the clinical patterns and therapeutic needs of COPD has not been the object of
interest. Paradoxically, the growing interest in comorbidity of COPD and its role as a determi-
nant of health status seems to overcome the research on the respiratory dimension of COPD.
The STORICO (STudio Osservazionale sulla caratteRizzazione dei sIntomi delle 24 ore nei
pazienti con broncopneumopatia cronica ostruttiva, Observational study on characterization of
24-h symptoms in patients with COPD) study assessed the association between circadian
rhythm of symptoms and several measures of health status [8]. Thus, it represents the ideal
framework to verify whether an in depth characterization of symptoms may allow define clini-
cal variants of COPD with distinctive classificatory and discriminatory properties. Thus, the
present paper is aimed to:
i. develop an innovative classification of COPD based on a multidimensional assessment
(named multi-dimensional phenotype) which takes into consideration primarily circadian
rhythm of symptoms, but also demographic characteristics, health related quality of life,
respiratory function and comorbidities.
ii. describe the patients belonging to the so-identified multi-dimensional phenotypes with
respect to body mass index, respiratory parameters, previous exacerbations, level of physi-
cal activity, quality of sleep, level of depression and anxiety and ongoing COPD pharmaco-
logical therapies.
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The final objective of such an attempt is to investigate the discriminatory properties and
potential clinical implications of this alternative classificatory method.
Materials and methods
Study subjects
The STORICO study (trial registration number: NCT03105999) enrolled subjects aged�50,
current/ex-smokers, with a diagnosis of stable COPD according to the GOLD 2014. The study
was approved by the ethical committee of the coordinating center (Fondazione Toscana G.
Monasterio Pisa, Italy) and was conducted in accordance with the Declaration of Helsinki and
the Good Clinical Practices guidelines for observational studies, complying with all require-
ments of local regulations. Patients provided written, informed consent before study participa-
tion. Subjects included, study design and methodology of the STORICO study are extensively
described elsewhere [8].
Patients with available information about early-morning, day- and night-time COPD
symptoms and clinical phenotype at enrollment were considered evaluable for analyses at
baseline; among these, the ones with available variables for (factor and cluster) analyses (below
detailed in Methods paragraph) were analyzed in this paper.
Study design
STORICO is an Italian observational cohort multicentre currently ongoing study conducted
in 40 pneumology centers. The study lasted from February 2016 (first subject first visit) to
June 2018 (last subject last visit); three visits were planned (baseline, 6- and 12-months follow
up).
Methods
At enrollment patients completed the Night-time, Morning and Day-time Symptoms of COPD
questionnaire [5] (hereafter named “symptoms questionnaire”) covering the frequency and
severity of COPD symptoms (breathlessness, coughing, bringing up phlegm or mucus, chest
tightness, chest congestion and wheezing) during each part of the day (night-time, early- and
day-time). Linguistic validation of the questionnaire in Italian was performed by the authors
to ensure accurate translation and a clear understanding of the questionnaire itself [5].
Health Related Quality of Life was evaluated by the St. George’s Respiratory Questionnaire
(SGRQ), in its Symptoms, Activity component and Impact scores [9–10] ranging between 0
(no impairment) and 100 (highest impairment), lower scores corresponding to better health.
Anxiety and depression levels were evaluated through the Hospital Anxiety and Depression
Scale (HADS) [11], a total score (ranging 0–42) and anxiety and depression subscales scores
(ranging 0–21) were computed, with higher scores indicating more distress.
The impact on sleep due to respiratory disease was assessed with the total score of COPD
and Asthma Sleep Impact Scale (CASIS) [12], ranging 0–100, with higher scores indicating
greater sleep impairment.
Physical activity was assessed by means of the categorical score (low, medium, high physical
activity) of the International Physical Activity Questionnaire (IPAQ) [13] on patients aged 15–
69 years. Spirometry was performed according to the recommendations of the American Tho-
racic Society (ATS) and the European Respiratory Society (ERS) and lung function measure-
ments were done with patients either standing or sitting with the nose clipped after at least 10
minutes rest [14].
The COPD multi-dimensional phenotype
PLOS ONE | https://doi.org/10.1371/journal.pone.0221889 September 13, 2019 3 / 15
Presence of relevant comorbidities according to clinical judgment, body mass index (BMI),
spirometry functional assessment and occurrence of exacerbations in the 5 years before base-
line were recorded too as far as ongoing pharmacological therapies for COPD (long-acting
beta-agonists (LABA), long-acting muscarinic antagonist (LAMA), inhaled corticosteroid
(ICS) and any combination, Others).
Analysis
In order to identify the multi-dimensional phenotypes (m-phenotypes), a multi-step approach
was followed.
STEP 1—Exploratory factor analysis. An exploratory factor analysis (EFA) was per-
formed to find independent latent constructs (factors), not directly measurable and influenc-
ing responses on observed variables. EFA is a variable reduction technique which does not
impose any preconceived structure on the outcome [15] and the observed variables included
in the model are a linear combination of the underlying factors.
The following items of the symptoms questionnaire were included in the factor analysis:
presence/absence of feeling short of breath or breathless (items 18a, 26a, 7a), cough (items 18b,
26b, 7b), bringing up phlegm or mucus (items 18c, 26c, 7c), each symptom evaluated during
the 24-hours (i.e. in the early-morning, day-time and night-time). The presence of the symp-
tom was coded as 1 and the absence as 0.
The value of the FEV1% of the predicted, of (symptoms, activity, impact) SGRQ scores,
demographic variables (age as continuous variable and gender coded as 1 for males and 2 for
females) and presence/absence of relevant comorbidities (cardiac ischemic disease, arterial
hypertension, heart failure, atrial fibrillation, diabetes, osteoporosis, depression, kidney insuffi-
ciency) were also included in the model (presence was coded as 1 and absence as 0). Orthogo-
nal VARIMAX rotation was applied; factors having an eigenvalue > 1.0 [16–17] and
individual variables with higher-than-0.5 loadings on retained factors were retained [18].
STEP 2 –Definition of classificatory variables. STEP 1 brought to identification of n fac-
tors. Then, the variables included in the n-th factor were evaluated and, whenever possible,
combined into a new classificatory variable (a classificatory variable for each factor was
defined).
STEP 3 –Cluster analysis. A cluster analysis with classificatory variables mentioned at
STEP 2 as input was performed. Average linkage was chosen as clustering method and average
distance between clusters equal to 0.70 was taken as reference to cut the dendrogram. Quality
of obtained clusters was evaluated by means of Semipartial R-squared (i.e. the loss of homoge-
neity due to combining two clusters to form a new cluster) and R-square (i.e. the proportion of
variance accounted for by the clusters).
Once identified, the different m-phenotypes were described with respect to BMI, spiromet-
ric parameters, number of previous exacerbations, quality of sleep, level of physical activity,
depression and anxiety and therapies for COPD at enrollment by means of median, 25th and
75th percentile for quantitative variables and absolute/relative frequency for categorical ones
within each class of m-phenotype. Moreover, although SGRQ scores were included in EFA,
SGRQ scores of m-phenotypes were compared to provide a comprehensive description of
health status.
Analysis of variance and Kruskal–Wallis test by ranks (on means and medians respectively)
and Fisher exact test (for categorical variables) were used to compare variables vs m-phenotype
(variable in 5 classes). Upon statistical significance of these tests, Mann-Whitney test on medi-
ans and Chi-square or Fisher exact tests were then applied to compare variables among specific
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pairs of m-phenotypes. Alpha (with Bonferroni correction) was set to 0.0004 considering the
total number of performed tests.
Statistical analysis was performed using SAS v9.4 and Enterprise Guide v7.1.
Results
Evaluable patients
Among the 683 COPD patients enrolled in the STORICO study, 606 (88.7%) subjects (age 71.4
±8.2 years, 75.1% males) were deemed evaluable for the analysis at baseline; 92 subjects were
then excluded because they had missing information on variables analyzed in the factor and
cluster analyses. Violations causing exclusion are shown in Fig 1.
So, 514 (mean±SD age: 71.4± 8.0 years) were deemed evaluable for the analyses here described.
Identification of m-phenotypes
STEP 1—Exploratory factor analysis. As results of the factors analysis, two factors
accounting for 82% of the total variability were retained. In Table 1, the factor loadings of indi-
vidual variables are shown. Factor 1 covers 58.6% of variability and its components are bring-
ing up phlegm or mucus and cough at any time of the day. Factor 2, explaining 23.2% of
variability, is composed by breathlessness at any time of the day and by SGRQ scores. A third
factor explained a reduced amount of variability (9.5%) and no variables had a factor loading
>0.5; so, it was not retained (output of factor analysis is reported in S1 Table and S1 Fig).
Fig 1. Patient disposition. The figure shows the number of patients enrolled at baseline, evaluable at baseline and
analyzed and the reasons for exclusion.
https://doi.org/10.1371/journal.pone.0221889.g001
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STEP 2 –definition of classificatory variables. The items of symptoms questionnaire
contributing to each factor (shown in grey in Table 1), were combined into 2 new 3-levels clas-
sificatory variables, namely “cough and/or bringing up phlegm or mucus” and “breathless-
ness”. The levels of them had increasing severity and were defined based on the frequency of
occurrence of the symptoms: (i) never during 24 hours, (ii) in the early-morning and/or day-
time, but never in night and (iii) in night and in the early-morning and/or day-time. The dis-
tribution of patients according to classificatory variables is shown in Table 2.
As SGRQ scores were retained in the second factor, they were described too within the lev-
els of “breathlessness” classificatory variable (Table 2). The (symptoms, activity, impacts)
scores significantly increased with level of severity of “breathlessness” (p-value < .0001 for
scores in all pairwise comparisons among “breathlessness” categories).
STEP 3 –cluster analysis. The cluster analysis run on previous mentioned classificatory
variables brought to five well defined clusters (Semipartial R-squared = 0.0260, R-square =
0.828; dendrogram is shown in S2 Table and S2 Fig). Such clusters are thereafter called m-phe-
notypes and they are below described.
M-phenotypes and circadian rhythm of symptoms
As shown in Fig 2 the m-phenotypes were characterized with regard to the circadian rhythm
of symptoms as follows:
Table 1. Factor 1, 2 and 3: Factor loadings.
Factor1 Factor2 Factor3
Bringing up phlegm or mucus (DAY-TIME) 0.76567 0.08402 0.06274
Bringing up phlegm or mucus (EARLY-MORNING) 0.75702 0.01087 0.04818
Cough (DAY-TIME) 0.71960 0.13606 -0.08848
Cough (EARLY-MORNING) 0.70750 0.12600 -0.09838
Bringing up phlegm or mucus (NIGHT-TIME) 0.58962 0.22837 0.10707
Cough (NIGHT-TIME) 0.57541 0.25280 -0.05965
Osteoporosis -0.09562 0.03034 -0.09537
SGRQ (activity score) 0.12888 0.79973 0.07505
SGRQ (impacts score) 0.22687 0.79011 -0.01568
SGRQ (symptoms score) 0.53305 0.66753 -0.03373
Breathlessness (EARLY-MORNING) 0.08851 0.65837 0.00826
Breathlessness (DAY-TIME) 0.09992 0.62001 -0.00822
Breathlessness (NIGHT-TIME) 0.18258 0.51578 -0.05343
Heart failure -0.01054 0.04432 0.02073
FEV1 of the predicted (%) -0.02539 -0.31861 -0.06188
Age at enrollment visit (years) -0.02229 0.08622 0.41033
Cardiac ischemic disease 0.02193 0.00187 0.33738
Arterial Hypertension 0.02618 0.00669 0.31897
Diabetes -0.00256 0.02765 0.28320
Kidney Insufficiency -0.03733 0.06382 0.22236
Atrial fibrillation -0.06142 0.02546 0.20271
Depression -0.08237 0.08699 -0.09820
Gender -0.09778 0.07278 -0.34109
Orthogonal VARIMAX rotation applied.
Factor loadings >0.5 are in bold.
https://doi.org/10.1371/journal.pone.0221889.t001
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1. No night-time symptoms (MILD COPD), n = 190. In this m-phenotype, 88 (46.3%) and
64 (33.7%) patients presented cough and/or bringing up phlegm or mucus in the early-
morning and day-time, respectively. Breathlessness was reported by 18 (9.5%) and 46
(24.2%) patients in the early-morning and day-time, respectively. Patients belonging to this
phenotype have no night symptoms.
2. Prevalent dyspnea in the early-morning and day-time, not by night (MILD EMPHYSE-
MATOUS), n = 94. Patients in this cluster suffered mainly from breathlessness in the early-
morning (n = 89, 94.7%) and day-time (n = 93, 98.9%). Diurnal cough or bringing up
phlegm or mucus was less frequent (63.8% in the early-morning, 59.6% in the day-time),
and night symptoms were distinctly rare (only breathlessness in 5.3% patients).
3. Nocturnal and diurnal cough and phlegm, no nocturnal dyspnea (SEVERE BRON-
CHITIC), n = 132. These patients suffered from cough and/or bringing up phlegm or
mucus, at night (n = 132, 100.0%), in the early-morning (n = 115, 87.1%) and day-time
(n = 109, 82.6%). Early-morning dyspnea is present in 47 (35.6%) patients and day-time in
65 (49.2%) patients.
4. Nocturnal and diurnal dyspnea (SEVERE EMPHYSEMATOUS), n = 18. At variance
with MILD EMPHYSEMATOUS, they presented breathlessness also during night (n = 18,
100%).
5. Higher frequency of symptoms, both cough and breathlessness, during 24h (SEVERE
MIXED COPD), n = 80. These patients had the highest frequency of symptoms during
24 hours: 100% of them had cough and breathlessness during night, 77 (96.3%) and 66
(82.5%) had these symptoms in the early-morning and 74 (92.5%) and 73 (91.3%) in the
day-time.
M-phenotypes vs BMI, respiratory parameters and number of
exacerbations
In Table 3 BMI, spirometric parameters at enrollment and previous exacerbations are
described. Patients with MILD COPD had a lower median (25th - 75th percentile) number of
exacerbations (1.0 (0.0–3.0)) than patients with SEVERE MIXED COPD (3.0 (1.0–5.0); p-
value < .0001). No other statistically significant differences emerged in analyzed parameters.
Table 2. Distribution of patients according to classificatory variables.
Classificatory variables (N, %) N = 514
Cough and/or bringing up phlegm or mucus
never during 24 hours 127 (24.7)
in the early-morning and/or day-time, but never in night 175 (34.1)
in night and in the early-morning and/or day-time 212 (41.2)
SGRQ scores
Median (25th - 75th percentile)
Breathlessness symptoms activity impacts
never during 24 hours 187 (36.4) 24.4 (13.1–41.3) 35.8 (23.3–47.7) 10.3 (5.5–17.8)
in the early-morning and/or day-time, but never in night 224 (43.6) 45.2 (35.0–57.2) 53.5 (41.3–64.3) 19.5 (12.5–33.8)
in night and in the early-morning and/or day-time 103 (20.0) 61.3 (50.6–75.3) 66.2 (55.1–79.5) 36.9 (21.8–57.1)
Percentages computed out of non-missing responses.
https://doi.org/10.1371/journal.pone.0221889.t002
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M-phenotypes vs quality of life, quality of sleep, level of physical activity,
anxiety and depression
Quality of life, as expressed by SGRQ scores, was better in MILD COPD than in patients of
other m-phenotypes (p-values tests MILD COPD vs each of the other m-phenotypes < .0001)
(Table 4). The SEVERE MIXED COPD m-phenotype had higher SGRQ symptoms score than
the other phenotypes (p-values < .0001) and higher SGRQ activity and impacts scores than in
MILD EMPHYSEMATOUS or SEVERE BRONCHITIC patients (p-values < .0001).
The patients in MILD COPD m-phenotype had better quality of sleep than patients of
other m-phenotypes (p-values < .0001) (Table 4). A negative grading of quality of sleep was
evident from MILD COPD to MILD EMPHYSEMATOUS and, then, SEVERE BRON-
CHITIC, SEVERE EMPHYSEMATOUS and SEVERE MIXED COPD.
The patients with MILD COPD had lower HADS total, anxiety and depression scores than
MILD EMPHYSEMATOUS or SEVERE MIXED COPD patients (p-values < .0001) and had
lower total and depression scores than SEVERE BRONCHITIC patients (p-values < .0001)
(Table 4). Differences between HADS scores of patients with SEVERE MIXED COPD vs
MILD EMPHYSEMATOUS or SEVERE BRONCHITIC patients were also significant (p-val-
ues< .0001).
Low physical activity, as expressed by the IPAQ score, largely prevailed in the patients with
SEVERE MIXED COPD and SEVERE EMPHYSEMATOUS m-phenotypes. However, differ-
ences between m-phenotypes did not reach significance (Table 4).
M-phenotypes vs pharmacological therapies for COPD
Pharmacological therapy did not differ significantly between m-phenotypes (Table 5).
Fig 2. Circadian rhythm of multidimensional phenotypes. The figure shows the circadian rhythm of symptoms in the 5 multidimensional phenotypes. Percentages of
symptoms during night-time, early-morning, day-time were calculated within m-phenotypes considering the patients suffering from the symptoms. A patient could
have multiple symptoms. MILD COPD: No night-time symptoms. MILD EMPHYSEMATOUS: Prevalent dyspnea in the early-morning and day-time, but not by
night. SEVERE BRONCHITIC: Nocturnal and diurnal cough and phlegm, no nocturnal dyspnea. SEVERE EMPHYSEMATOUS: Nocturnal and diurnal dyspnea.
SEVERE MIXED COPD: Higher frequency of symptoms during 24h.
https://doi.org/10.1371/journal.pone.0221889.g002
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Discussion
We found that the circadian rhythm of the three main respiratory symptoms and an index of
disease-related health status could classify the vast majority of patients, whereas comorbidity,
FEV1, age and gender added little to the classificatory power of the model. Indeed, based on
these components of the latent factors, it was possible to identify five multidimensional pheno-
types with distinctive pattern of disease (Fig 2): the MILD COPD, the MILD EMPHYSEMA-
TOUS, the SEVERE BRONCHITIC, the SEVERE EMPHYSEMATOUS and the SEVERE
MIXED COPD.
Taken together, these findings point out that the “core business” of COPD, the clinical one,
can distinguish patients with different disease profiles. The fact that two factors, extracted
through a parsimonious model, could explain 82% of intrinsic variability testifies to the
strength of the classificatory procedure and to the overall quality of the clustering based mainly
on clinical ground.
Consistent with the classical distinction of bronchitic and emphysematous phenotypes, dys-
pnea and productive cough contributed to define two well distinguished dimensions of the dis-
ease. Accordingly, attempts at optimally caring the individual COPD patient should have
individually tailored goals: relieving bronchial obstruction might not be the main objective of
the care in patients burdened mainly or exclusively with productive cough, whereas relieving
dyspnea could be the core therapeutic goal in another group of patients, and the timing of
Table 3. Multidimensional phenotype vs BMI, respiratory parameters and previous COPD exacerbations at enrollment.
MILD COPD MILD EMPHYSEMATOUS SEVERE BRONCHITIC SEVERE EMPHYSEMATOUS SEVERE MIXED COPD
BMI n = 188 n = 92 n = 132 n = 18 n = 79
26.6 (24.1–
28.7)
26.8 (24.2–29.8) 26.9 (24.3–30.1) 26.9 (23.7–30.1) 26.5 (23.5–30.1)
N of COPD exacerbations/
year
(5 years before baseline)
n = 177 n = 91 n = 118 n = 15 n = 70
1.0 (0.0–3.0) 2.0 (0.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–5.0) 3.0 (1.0–5.0)
FEV1 of the predicted (%) n = 190 n = 94 n = 132 n = 18 n = 80
67.0 (53.0–
84.0)
61.5 (52.0–75.0) 62.6 (52.5–81.0) 58.5 (50.0–71.0) 54.5 (39.5–78.9)
RV (L) n = 104 n = 61 n = 70 n = 7 n = 34
3.1 (2.5–4.0) 3.8 (3.0–5.0) 3.0 (2.5–3.9) 3.0 (2.5–4.3) 3.2 (2.4–3.8)
TLC (L) n = 101 n = 61 n = 69 n = 7 n = 33
6.4 (5.5–7.4) 6.8 (5.9–7.8) 6.1 (5.2–7.1) 6.6 (4.8–7.3) 5.9 (5.0–6.7)
RV/TLC n = 103 n = 34 n = 69 n = 7 n = 34
0.5 (0.4–0.6) 0.6 (0.5–0.7) 0.5 (0.4–0.6) 0.5 (0.4–0.6) 0.5 (0.4–0.6)
DLCO of the predicted (%) n = 76
72.6 (55.5–
84.0)
n = 42
67.0 (49.7–81.1)
n = 47
65.7 (45.0–81.0)
n = 8
53.5 (39.4–71.5)
n = 21
67.0 (58.0–74.0)
BMI: Body mass index; RV: Residual Volume; TLC: Total lung capacity; DLCO: diffusing capacity of the lung for carbon monoxide.
Median (25th - 75th percentile) were showed.
MILD COPD: No night-time symptoms.
MILD EMPHYSEMATOUS: Prevalent dyspnea in the early-morning and day-time, but not by night.
SEVERE BRONCHITIC: Nocturnal and diurnal cough and phlegm, no nocturnal dyspnea.
SEVERE EMPHYSEMATOUS: Nocturnal and diurnal dyspnea.
SEVERE MIXED COPD: Higher frequency of symptoms during 24h.
https://doi.org/10.1371/journal.pone.0221889.t003
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Table 4. Multidimensional phenotype vs quality of life, quality of sleep, level of physical activity and anxiety and depression at enrollment.
MILD COPD MILD EMPHYSEMATOUS SEVERE BRONCHITIC SEVERE EMPHYSEMATOUS SEVERE MIXED COPD
N 190 94 132 18 80
SGRQ scores
symptoms 24.2 (12.4–37.0) 50.8 (38.4–58.6) 46.7 (35.7–59.3) 46.5 (30.9–58.2) 67.9 (57.7–76.5)
activity 36.2 (24.1–47.7) 53.6 (47.7–66.2) 47.7 (35.6–62.6) 63.3 (54.4–69.1) 71.5 (59.5–82.7)
impacts 10.3 (5.5–16.9) 19.3 (13.9–31.4) 21.3 (11.7–36.6) 28.9 (18.3–46.7) 41.1 (24.9–59.7)
N 188 94 132 17 80
CASIS total score
5.7 (0.0–11.4) 10.0 (5.7–17.1) 20.0 (11.4–31.4) 28.6 (11.4–37.1) 40.0 (25.7–48.6)
N 178 92 123 17 74
HADS scores
Total 5.0 (2.0–9.0) 9.0 (6.0–15.0) 8.0 (4.0–14.0) 9.0 (7.0–14.0) 16.0 (12.0–21.0)
Anxiety 2.0 (1.0–5.0) 5.0 (2.0–8.0) 4.0 (1.0–7.0) 5.0 (3.0–8.0) 8.0 (6.0–10.0)
Depression 2.0 (1.0–4.0) 5.0 (2.0–8.0) 4.0 (2.0–8.0) 4.0 (3.0–6.0) 8.0 (5.0–10.0)
N 66 35 38 4 29
IPAQ–level of physical activity (n;%)
Low 14 (21.2) 8 (22.9) 10 (26.3) 2 (50.0) 13 (44.8)
Moderate 50 (75.8) 27 (77.1) 28 (73.7) 2 (50.0) 16 (55.2)
High 2 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
If not otherwise specified the median (25th - 75th percentile) were showed.
MILD COPD: No night-time symptoms.
MILD EMPHYSEMATOUS: Prevalent dyspnea in the early-morning and day-time, but not by night.
SEVERE BRONCHITIC: Nocturnal and diurnal cough and phlegm, no nocturnal dyspnea.
SEVERE EMPHYSEMATOUS: Nocturnal and diurnal dyspnea.
SEVERE MIXED COPD: Higher frequency of symptoms during 24h.
https://doi.org/10.1371/journal.pone.0221889.t004
Table 5. Multidimensional phenotype vs pharmacological therapies for COPD at enrollment.
MILD COPD MILD EMPHYSEMATOUS SEVERE BRONCHITIC SEVERE EMPHYSEMATOUS SEVERE MIXED COPD
(N = 190) (N = 94) (N = 132) (N = 18) (N = 80)
COPD pharmacological therapy ongoing at enrollment (N; %)
No therapy 25 (13.2) 17 (18.1) 20 (15.2) 1 (5.6) 8 (10.0)
Triple therapy 45 (23.7) 28 (29.8) 51 (38.6) 3 (16.7) 28 (35.0)
LABA+LAMA 48 (25.3) 23 (24.5) 25 (18.9) 6 (33.3) 22 (27.5)
LAMA Alone 38 (20.0) 12 (12.8) 13 (9.8) 2 (11.1) 12 (15.0)
ICS+LABA 26 (13.7) 7 (7.4) 19 (14.4) 4 (22.2) 8 (10.0)
OTHER 8 (4.2) 7 (7.4) 4 (3.0) 2 (11.1) 2 (2.5)
Triple therapy is defined as any combination of long-acting beta-agonists (LABA), long-acting muscarinic antagonist (LAMA), inhaled corticosteroid (ICS) in fixed
dose combination or not.
Other therapies include LABA alone, ICS+LAMA, SABA, SAMA, Theophylline, Oral or IV Corticosteroids.
Percentages computed within m-phenotypes.
MILD COPD: No night-time symptoms.
MILD EMPHYSEMATOUS: Prevalent dyspnea in the early-morning and day-time, but not by night.
SEVERE BRONCHITIC: Nocturnal and diurnal cough and phlegm, no nocturnal dyspnea.
SEVERE EMPHYSEMATOUS: Nocturnal and diurnal dyspnea.
SEVERE MIXED COPD: Higher frequency of symptoms during 24h.
https://doi.org/10.1371/journal.pone.0221889.t005
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symptoms further adds to the decision making [19]. This seemingly obvious finding has
important practical implications. Indeed, FEV1 or the six minute walked distance should not
be considered universal effect measures in randomized clinical trials. While these indexes have
great merit as overall indexes of disease severity, they might not catch the core expression of
COPD and, then, the main expected benefit of therapy in an important proportion of patients.
The findings of the current study strongly advocate for the design of multi-outcome or
patient-tailored RCTs in the perspective of precision medicine. Pursuing the patient centered
objective of care is also expected to increase adherence to therapy. Indeed, the surprisingly
high rate of non-adherence to inhaled medication, including inappropriate inhaler use by
COPD patients [20] as well as the usually high rate of enrollees lost in RCT due to withdrawn
consent [21–22] might reflect the perception of the care as missing the own needs by many
patients.
The circadian rhythm of symptoms played a major classificatory role. Indeed, MILD
COPD and MILD EMPHYSEMATOUS patients never/very unfrequently experience night-
time symptoms, which, instead, are always present in SEVERE EMPHYSEMATOUS, SEVERE
BRONCHITIC and SEVERE MIXED COPD m-phenotypes. Several evidences support the
role of circadian rhythm of symptoms in defining the clinical spectrum of COPD. Indeed,
bronchial obstruction is strictly related to nocturnal symptoms [3] and wheezing has been
reported to be the most common of them [23–24]. Interestingly, night time symptoms quali-
fied as the main correlate of depression in the Assess study [5]. However, Physicians signifi-
cantly underestimate the impact of COPD on the patient’s ability to get up in the morning and
on sleep [6]. Unfortunately, only in the last few years attention has been paid to nocturnal
symptoms, but mainly to empirically modulate the pharmacological therapy rather than to rig-
orously understand COPD heterogeneity.
Selected innovative models have recently been proposed to classify COPD patients. They
variably rely upon comorbidities and complications of COPD [25–26] or on a comprehensive
respiratory function assessment [27]. However, they do not rate symptoms according to a stan-
dardized procedure. This likely explains why symptoms played a major classificatory role in
ours and not in these models. Thus, two different phylosophies, respectively centered on the
non respiratory and the respiratory dimension of COPD, found previous model and the pres-
ent one. Only the longitudinal observation will allow compare discriminative and prognostic
properties of these models. On the other hand, classificatory models including analytes such as
cytokines or genetic markers are intended to define idyotypes and not phenotypes and, thus,
are not comparable with our prettily clinical and, then, phenotypic model [28]. Also the Span-
ish clinical classification of COPD patients differs from ours because it simply aims at assessing
the perceived prevalence of predefined clinical phenotypes [29]. Given patients were on regu-
lar topical therapy for COPD, the important prevalence of night time symptoms and severely
impaired health status testifies to the poor quality of the overall pharmacological approach.
Analogously, in a European survey from primary care centers two thirds of COPD patients
complained of dyspnea despite current treatment [30]; an even higher percentage of subjects
suffered from chronic cough, and this was similar across all severity COPD stages. Otherwise,
the important clinical differences among clusters suggest that many patients are expected to
gain the greatest benefit from non- pharmacological measures contrasting phlegm and mucus.
Indeed, being recognized as a multidimensional and heterogeneous condition, COPD should
be the object of personalized care.
The fact that the SGRQ contributed to categorize COPD patients further confirms that
health status is something different from and, thus, may not be merely expressed by symptoms.
Interestingly, dyspnea associates with SGRQ in latent factor 2, as if dyspnea were the main cor-
relate of perceived health status. This partly reflects the structure of the SGRQ, which largely
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relates the perceived status to physical activities which are obviously limited by dyspnea. Fur-
thermore, this finding stresses the need of including an index of health status among the
instruments rating COPD severity and the effects of therapeutic interventions.
Limitations of the study deserve consideration. First, we chose the classificatory variables
with the aim of limiting recall bias. This is the reason why we selected the Night-time, Morning
and Day-time Symptoms of COPD questionnaire, with a recall period of a week. Indeed, we
based the classification on variables reflecting the patient’s condition at the time of enrollment
in order to prevent any classificatory bias linked to uncertain definition of variables requiring
an accurate recall, such as frequency of exacerbations. Second, the definition of a clinical vari-
ant or subtype of COPD should be founded on the clinical pattern in the absence of any ther-
apy. However, it is almost impossible to recruit patients with severe COPD free from
pharmacological treatment, and those untreated likely represent a poorly representative sam-
ple. Third, the observed clinical variants of COPD should not be considered true phenotypes.
Instead, phenotypes are intrinsically stable, and only the follow-up will assess cluster stability.
Thus, the full spectrum of classificatory properties of our model will emerge only at the end of
the follow-up phase of the study, which is currently ongoing. Finally, our patients had mean
age of 71.4 years; thus, present results might not fully apply to the growing fraction of COPD
patients classified as old (age over 75 years), which pose distinctive diagnostic and therapeutic
problems [31].
Conclusions
Despite these limitations, our study emphasizes the clinical meaning of the circadian rhythm
of COPD symptoms. It suggests that a classificatory approach based on the respiratory clinical
dimension of COPD succeeds in identifying classes of patients with distinctive features. In an
era characterized by a growing interest in extra pulmonary features of COPD, which obviously
are worthy of consideration, our study redirects the attention of physicians to the elementary
truth that COPD is a primarily respiratory disease and an accurate clinical rating of patient’s
status is the first task required to any physician caring for a COPD patient.
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